NRBO vs. FLGC, GLTO, APM, BIVI, ORGS, KALA, GLYC, NNVC, NRSN, and INDP
Should you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Flora Growth (FLGC), Galecto (GLTO), Aptorum Group (APM), BioVie (BIVI), Orgenesis (ORGS), KALA BIO (KALA), GlycoMimetics (GLYC), NanoViricides (NNVC), NeuroSense Therapeutics (NRSN), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
In the previous week, NeuroBo Pharmaceuticals had 5 more articles in the media than Flora Growth. MarketBeat recorded 8 mentions for NeuroBo Pharmaceuticals and 3 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.64 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.
NeuroBo Pharmaceuticals has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
NeuroBo Pharmaceuticals received 14 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 59.09% of users gave Flora Growth an outperform vote.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -75.33%. Flora Growth's return on equity of -60.26% beat NeuroBo Pharmaceuticals' return on equity.
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Flora Growth.
1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
NeuroBo Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 152.53%. Flora Growth has a consensus target price of $7.00, indicating a potential upside of 410.95%. Given Flora Growth's higher possible upside, analysts plainly believe Flora Growth is more favorable than NeuroBo Pharmaceuticals.
Summary
Flora Growth beats NeuroBo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get NeuroBo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroBo Pharmaceuticals Competitors List
Related Companies and Tools
